Keith A A Fox, Priscilla Velentgas, A John Camm, Jean-Pierre Bassand, David A Fitzmaurice, Bernard J Gersh, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Frank Misselwitz, Karen S Pieper, Alexander G G Turpie, Freek W A Verheugt, Elizabeth Dabrowski, Kaiyi Luo, Liza Gibbs, Ajay K Kakkar
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with antiplatelet (AP) drugs in addition to OAC, with or without documented vascular disease or other indications for AP therapy. Objective: To investigate baseline characteristics and outcomes of patients who were prescribed OAC plus AP therapy vs OAC alone...
February 5, 2020: JAMA Network Open